A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Recruiting now
Conditions studied: Follicular Lymphoma
In brief
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
Key facts
- Study ID
- NCT06794268
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- People needed
- 300
- Starts
- 2025-02-04
- Expected to finish
- 2044-08-31
- Last updated by the study team
- 2025-02-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA
You may not qualify if…
- Participants known to be participating in investigational studies at the time of liso-cel, infusion
- Participants treated with liso-cel for the treatment of R/R FL Grade 3b
- Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product
Where it is running
- CIBMTR — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.